Creo Medical (CREO) is perhaps one of AIM’s least glamorous companies. It is focused on the emerging field of surgical endoscopy – a multi-billion-pound market which is expanding due to the advent of colorectal cancer screening around the world.
Creo is developing a suite of products based on its transformational CROMA electrosurgery advanced energy platform. Its first – the rather oddly named RS2 Speedboat – enables the removal of cancerous and pre-cancerous growths in the gastro-intestinal tract or large legions in the bowel. Lovely stuff.
For the 16,000 British people who are diagnosed with bowel cancer every year this technology is very exciting. More so now that is has successfully treated its first set of patients in the US, following positive trials in UK, South Africa, Mainland Europe. Clinical trial success will provide a platform to allow eventual worldwide approval.
The company is busy training surgeons how to use the technology which they hope will one day be used in…
Register to continue reading this article.
Already a member? Login
For access to the top news and insights from the investment worldREGISTER FREE TODAY